Interview with Dr James Garner, CEO of Kazia Therapeutics
-
Regulatory November 21, 2022Vivesto appoints Erik Kinnman as CEO
-
Regulatory November 21, 2022Nomination Committee appointed for the 2023 Annual General Meeting in Vivesto
-
Regulatory November 17, 2022Interim report for the period January 1, 2022 – September 30, 2022
Vivesto published its Q3 report for 2022 on November 17, 2022, at 08.00 am CET.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program
We published our Q2 results today, which show continued cost control, with a reduction in operating expenses.
#oncology #biotech
Interim report for the period January 1, 2022 – June 30, 2022 - Vivesto
SIGNIFICANT EVENTS DURING THE SECOND QUARTER In April Daniel Tesfa was appointed Chief Medical Officer. In April Vivesto signed an agreement with...
www.vivesto.com
For #investors and #media:
Today Inceptua launched Apealea® in Germany. This is great news for patients but also for Vivesto’s business as we are eligible for royalties on any sales.
#oncology #biotech
Vivesto notes the launch of Apealea® in Germany by Inceptua - Vivesto
Solna, Sweden, 15 August 2022 – Vivesto AB, an oncology-focused specialty pharmaceutical company, is pleased to note...
www.vivesto.com
This #MensHealthWeek have a look at this campaign by @menshealthforum all about how to carry out a MAN-MOT. Your car gets one regularly so why not all men? This article shows how to do your own and help early diagnosis of Prostate cancer.
Read more here:
DIY Man MOT
Your car gets one regularly but what about you? No, not a parking ticket, an MOT. Giving your body a once-over...
bit.ly